Cavrotolimod is under clinical development by Bluejay Therapeutics and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cavrotolimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cavrotolimod overview
Cavrotolimod (AST-008) is under development for the treatment of hepatitis B.
It was also under development for the treatment of solid tumors such as lung cancer, breast cancer, lymphoma, colorectal cancer, melanoma, bladder cancer, Merkel cell carcinoma, cutaneous squamous cell carcinoma, head and neck cancer squamous cell carcinoma and hematological cancer. It is administered subcutaneously, intravenously and through intratumoral route. The drug candidate is developed based on the spherical nucleic acid (SNA) technology platform.
Bluejay Therapeutics overview
Bluejay Therapeutics focuses on development of cures for infectious diseases with target to chronic HBV infection. Bluejay Therapeutics is headquartered in Hillsborough, California, the US.
For a complete picture of Cavrotolimod’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
